← Bio Talent Intelligence

BANSEOG BIO TALENT INTELLIGENCE

CDMO · COMPANY INTELLIGENCE

ST
PHARM

We look for people who turn new technology and customer requirements into qualified, repeatable productive capacity through process translation, scale-up and GMP execution.

TALENT PATTERN · 01The scarcer experience may be not scaling a process, but turning the scaled process into qualified commercial capacity.
7 roles & capabilities observed4 business & hiring changes observed2 Talent Patterns published

TALENT PATTERNS

See which experience may become scarce first.

01SCALE-UP TO QUALIFIED CAPACITY

TALENT CAPABILITY

Scale-Up to Qualified Capacity

Industrialization Builder

The capability to move a research or clinical process to larger scale and close quality, regulatory and GMP requirements until it becomes repeatable commercial capacity.

Increasing batch scale is different from redesigning the process, analytical and quality conditions that break at scale and finishing a qualified productive system.

Core capability
  • Process Translation
  • Scale-Up
  • Qualification
  • Commercial Manufacturing
Experience that strengthens it
  • Process Development
  • Tech Transfer
  • Manufacturing
  • QA/QC
  • Regulatory Affairs

The scarcer experience may be not scaling a process, but turning the scaled process into qualified commercial capacity.

We look beyond larger batches to the experience of connecting process change, technology transfer, quality and regulatory requirements with repeatable GMP manufacturing.

Why nowST Pharm reports more than 15 years of oligonucleotide manufacturing, technology-transfer and scale-up experience, including GMP oligos for Phase III and commercial uses, while expanding oligonucleotide capacity toward 14.0 mole in 2026.

Company & HR

When moving a pilot or clinical process toward commercial manufacturing, what broke at scale and what did you redesign?

Who should we look at first?Process Development / Tech Transfer / Manufacturing depth plus scale-up, qualification and GMP-commercialization experience
Where should we look?

Look beyond identical titles to people across Process, Tech Transfer, QA/QC, Regulatory and Manufacturing who have closed a commercial-ready handoff.

What should we do next?

Validate the candidate’s own decisions around process changes, analytical or quality impact, qualification and the final GMP state rather than batch size or years alone.

Hiring playbook

Search rule

Prioritize end-to-end ownership that moved a pilot or clinical process into commercial-ready manufacturing over years in Process Development or Manufacturing alone.

Evidence to test in interview

Ask what failed at scale, which process, analytical or quality conditions changed, and what GMP or commercial state was ultimately reached.

Build internally

Define ownership across Process Development → Tech Transfer → Scale-Up → Quality/Qualification → Manufacturing handoffs.

Request analysis of this talent market →
View evidence7
Roles & capabilities
ManufacturingPersistent
Process DevelopmentObserved again
Tech TransferObserved again
Quality AssurancePersistent
Business changes
ST Pharm connects mRNA-LNP technology to a Banwol GMP production platformSource ↗
ST Pharm expands oligonucleotide capacity while preserving tech-transfer and scale-up depthSource ↗
ST Pharm sustains a development-to-commercial cGMP manufacturing modelSource ↗
02CUSTOMER-TO-CAPACITY TRANSLATION

TALENT CAPABILITY

Customer-to-Capacity Translation

Customer-Manufacturing Translator

The capability to convert external customer requirements into internal process, quality and regulatory conditions and connect them to manufacturable capacity and delivery.

Communicating with customers is different from translating a requirement into manufacturing specifications, process decisions and quality constraints and closing the loop through GMP production.

Core capability
  • Customer Requirement
  • Technical Translation
  • Quality/Regulatory Alignment
  • Manufacturing Delivery
Experience that strengthens it
  • Tech Transfer
  • Process Development
  • Regulatory Affairs
  • QA/QC
  • Manufacturing

Understanding a customer requirement is different from turning it into manufacturable conditions and capacity.

We look for experience translating external requirements into technical specifications, process decisions, quality or regulatory requirements and actual manufacturing delivery.

Why nowST Pharm highlights roughly three decades of global client relationships and development-to-commercial cGMP manufacturing, with manufacturing, QC/QA and R&D at Sihwa and Banwol and regulatory-commercial functions in Seoul.

Company & HR

Describe a project where the customer’s requested condition conflicted with manufacturing reality. What changed, how was it aligned, and did it reach production?

Who should we look at first?Tech Transfer / Process / PM / QA-RA / Manufacturing depth plus customer-to-production translation experience
Where should we look?

Look beyond commercial or PM titles to Process, Tech Transfer, Quality, Regulatory and Manufacturing people who converted customer requirements into executable production conditions.

What should we do next?

Ask what was technically impossible, what alternative was designed, how quality/regulatory impact was handled, how the customer agreed, and whether it reached GMP delivery.

Hiring playbook

Search rule

Prioritize boundary ownership where external requirements conflicted with manufacturing reality and the candidate redesigned technical, quality or regulatory conditions through delivery.

Evidence to test in interview

Ask for one case covering the requested condition, manufacturing constraint, alternative design, quality/regulatory impact, customer agreement and final production result.

Build internally

Define translation ownership and acceptance criteria between Client Technical Interface and Process, Quality, Regulatory and Manufacturing.

Request analysis of this talent market →
View evidence7
Roles & capabilities
ManufacturingPersistent
Process DevelopmentObserved again
Tech TransferObserved again
Quality AssurancePersistent
Business changes
ST Pharm connects mRNA-LNP technology to a Banwol GMP production platformSource ↗
ST Pharm expands oligonucleotide capacity while preserving tech-transfer and scale-up depthSource ↗
ST Pharm sustains a development-to-commercial cGMP manufacturing modelSource ↗

CURRENT EVIDENCE

Start with what is currently observed.

Current roles & capabilities

ManufacturingContinuing signalPersistent
Process DevelopmentContinuing signalObserved again
Tech TransferContinuing signalObserved again
Quality AssuranceContinuing signalPersistent
Quality ControlContinuing signalPersistent
Regulatory AffairsContinuing signalPersistent
Research ScienceContinuing signalObserved again
Repeatedly observed pressure

Process Development · Tech Transfer · Research Science · Manufacturing · Quality Assurance · Quality Control

Business & hiring changes

Date not confirmed · Pipeline changeST Pharm connects mRNA-LNP technology to a Banwol GMP production platform

Newer RNA technology is being integrated with a physical GMP production node rather than remaining a research-only capability.

Source ↗
Date not confirmed · Manufacturing changeST Pharm expands oligonucleotide capacity while preserving tech-transfer and scale-up depth

Oligonucleotide capacity rises across Sihwa and Banwol while technology transfer, scale-up and late-stage/commercial GMP manufacturing remain core service requirements.

Source ↗
Date not confirmed · Manufacturing changeST Pharm sustains a development-to-commercial cGMP manufacturing model

The company’s long regulatory record and development-to-commercial service model show manufacturing capability being repeatedly fixed into qualified operating standards.

Source ↗
2026-06-19 · PartnershipST Pharm adds AI-assisted mRNA design to the SMARTCAP development layer

The joint research links AI sequence optimization to a proprietary capping platform with intended use in CDMO and internal R&D.

Source ↗
BANSEOG ANALYSISST Pharm repeatedly turns new modalities and customer programs into qualified productive capacity

CURRENT TALENT MARKET

Then see the talent market moving around it.

TALENT & CAREER

How far can my experience transfer?

No evidence-backed adjacent career path is currently linked.

COMPANY & HR

Who else is looking at the same talent?

No evidence-backed talent-competitor relationship is currently linked.